Ipratropium Adultes Arrow

Ipratropium bromide, the active ingredient in Ipratropium Adultes Arrow, is an anticholinergic (muscarinic antagonist) presented as an inhalation solution for inhalation use. It is used to treat bronchospasm in adults with asthma or chronic obstructive pulmonary disease (COPD).

GNH USA supplies Ipratropium Adultes Arrow as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipratropium bromide is a bronchodilator that acts on the muscarinic receptors of the airway smooth muscle.

Asthma: Provides bronchodilation to improve airflow and reduce symptoms in patients with reversible airway obstruction. Chronic obstructive pulmonary disease (COPD): Reduces bronchoconstriction to improve lung function and ease breathing in stable COPD.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth: reduced salivary secretion. - Cough: irritation of the airway during inhalation. - Throat irritation: mild soreness or discomfort. - Headache: transient mild headache. - Dizziness: occasional light‑headed sensation. - Nasal congestion: mild nasal blockage.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Angioedema: swelling of face, lips, or tongue. - Severe allergic reaction: rash, itching, or anaphylaxis. - Urinary retention: difficulty emptying the bladder. - Glaucoma exacerbation: increased intra‑ocular pressure. - Cardiovascular effects: tachycardia or palpitations.

Before prescribing ipratropium bromide, clinicians should consider patient‑specific factors and safety measures.

Assess renal function: adjust use in severe renal impairment. Monitor for anticholinergic effects: watch for dry mouth, urinary retention, or constipation. Avoid in patients with known hypersensitivity to ipratropium or atropine derivatives. Use caution in patients with glaucoma or prostatic hypertrophy. Store at room temperature: keep in the original container, protect from moisture and light.

Ipratropium bromide can interact with other medications that affect the cholinergic system or bronchodilation.

Major Interactions (Avoid): - Beta‑2 agonists: may reduce the bronchodilator effect of ipratropium when used without medical supervision. - MAO inhibitors: increased anticholinergic effects; concurrent use should be avoided.

Moderate Interactions (Monitor Closely): - Antihistamines: may increase anticholinergic load; monitor for excessive dryness. - Theophylline: additive bronchodilation may occur; observe for side‑effects. - Other anticholinergics: combined use raises risk of systemic anticholinergic toxicity.